Eli Lilly inks $630M deal for Phase 1 MASH candidatenews2025-02-10T20:15:03+00:00February 10th, 2025|Endpoints News|
Decade after $8B deal, Roche offloads InterMune to mysterious specialty pharmanews2025-02-10T14:53:43+00:00February 10th, 2025|Endpoints News|
Bain buys Mitsubishi Tanabe Pharma in $3.3B bet on Japannews2025-02-07T16:06:41+00:00February 7th, 2025|Endpoints News|
Acelyrin and Alumis to merge in deal combining cash, assetsnews2025-02-06T23:07:11+00:00February 6th, 2025|Endpoints News|
J&J, Intra-Cellular quickly sealed $14B deal as three others passed on buying the neuro drugmakernews2025-02-06T16:17:39+00:00February 6th, 2025|Endpoints News|
Teladoc to buy Catapult Health for $65Mnews2025-02-05T22:05:07+00:00February 5th, 2025|Endpoints News|
Revance, Crown near deal close after earlier bidding warnews2025-02-05T18:42:58+00:00February 5th, 2025|Endpoints News|
Pfizer says it has at least $10B available for deals in 2025news2025-02-04T20:40:32+00:00February 4th, 2025|Endpoints News|
Biogen’s research chief talks China, neuropsychiatry and pipeline plannews2025-02-03T18:45:35+00:00February 3rd, 2025|Endpoints News|
Roche aims for derisked deals and ruthless portfolio cuts in 2025news2025-01-30T11:41:56+00:00January 30th, 2025|Endpoints News|
